Cancer drug warning

Helen Palmer Jul 24, 2006
HTML EMBED:
COPY

Cancer drug warning

Helen Palmer Jul 24, 2006
HTML EMBED:
COPY

TEXT OF STORY

MARK AUSTIN THOMAS: In the last five years, a class of so-called miracle drugs has emerged. That’s made some forms of cancer chronic, rather than deadly. But new research suggests some of these pricey new drugs might have a dangerous side-effect. From the Health Desk at WGBH, Helen Palmer has more.


HELEN PALMER: Gleevec, a drug made by biotech company Novartis, costs about $25,000 a year. It completely suppresses leukemia in 70 percent of patients, but that’s not the whole story.

THOMAS FORCE: Gleevec, while a phenomenally effective drug in leukemias can /// cause patients to go into heart failure. :

Cardiologist Thomas Force of Thomas Jefferson University says 10 patients on Gleevec suffered serious heart problems, so his team studied the drug in mice and heart cells in the lab.

Force says not only does Gleevec damage hearts in some patients, other new cancer drugs that target the same proteins could also be dangerous.

But that’s not a reason to shun them, says Larry Sasich of the Licom School of Pharmacy.

LARRY SASICH: Every patient has a different level of risk that they’re willing to accept.

Patients should be informed of the dangers, and carefully monitored, says Sasich. Analysts say the heart findings should spur the development of safer cancer drugs.

In Boston, I’m Helen Palmer for Marketplace.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.